CELLECTIS - ADR (CLLS)

US15117K1034 - ADR

2.65  -0.02 (-0.75%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CELLECTIS - ADR

NASDAQ:CLLS (3/28/2024, 8:02:24 PM)

2.65

-0.02 (-0.75%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap190.14M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CLLS Daily chart

Company Profile

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

Company Info

CELLECTIS - ADR

8, rue de la Croix Jarry

Paris ILE-DE-FRANCE 75013

P: 33181691600

CEO: Andre Choulika

Employees: 345

Website: https://www.cellectis.com/

CLLS News

News Image25 days ago - Cellectis Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

PARIS, 04 mars 2024 (GLOBE NEWSWIRE) -- (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext...

News Image25 days ago - Cellectis Inc.Monthly information on share capital and company voting rights

PARIS, March 04, 2024 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext...

News Image2 months ago - Cellectis Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

      (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 02 févr. 2024 (GLOBE NEWSWIRE) -- Place de cotation :...

News Image2 months ago - Cellectis Inc.Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext...

News Image2 months ago - Seeking AlphaCellectis draws down second tranche under EIB credit facility (NASDAQ:CLLS)

Cellectis (CLLS) said it has drawn down a second tranche of EUR 15M under a credit facility agreement with the European Investment Bank, or EIB. Read more here.

News Image2 months ago - Cellectis Inc.Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

CLLS Twits

Here you can normally see the latest stock twits on CLLS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example